Thyroid ultrasound (US) is a key examination for the man- agement of thyroid nodules. Thyroid US is easily accessible, noninvasive, and cost-effective, and is a mandatory step in the workup of thyroid nodules. The main disadvantage of the method is that it is operator dependent. Thyroid US as- sessment of the risk of malignancy is crucial in patients with nodules, in order to select those who should have a fine nee- dle aspiration (FNA) biopsy performed. Due to the pivotal role of thyroid US in the management of patients with nod- ules, the European Thyroid Association convened a panel of international experts to set up European guidelines on US risk stratification of thyroid nodules. Based on a review of the literature and on the American Association of Clinical Endo- crinologists, American Thyroid Association, and Korean guidelines, the panel created the novel European Thyroid Imaging and Reporting Data System, called EU-TIRADS. This comprises a thyroid US lexicon; a standardized report; defini- tions of benign and low-, intermediate-, and high-risk nod-ules, with the estimated risks of malignancy in each catego- ry; and indications for FNA. Illustrated by numerous US im- ages, the EU-TIRADS aims to serve physicians in their clinical practice, to enhance the interobserver reproducibility of de-scriptions, and to simplify communication of the results...

Objective:To provide evidence-based recommendations regarding the use of advanced technology in the management of persons with diabetes mellitus to clinicians, diabetes-care teams, health care professionals, and other stakeholders. Methods:The American Association of Clinical Endocrinology (AACE) conducted literature searches for relevant articles published from 2012 to 2021. A task force of medical experts developed evidence-based guideline recommendations based on a review of clinical evidence, expertise, and informal consensus, according to established AACE protocol for guideline development. MainOutcomeMeasures:Primary outcomes of interest included hemoglobin A1C, rates and severity of hypoglycemia, time in range, time above range, and time below range. Results:This guideline includes 37 evidence-based clinical practice recommendations for advanced diabetes technology and contains 357 citations that inform the evidence base. Recommendations:Evidence-based recommendations were developed regarding the efficacy and safety of devices for the management of persons with diabetes mellitus, metrics used to aide with the assessment of advanced diabetes technology, and standards for the implementation of this technology. Conclusions:Advanced diabetes technology can assist persons with diabetes to safely and effectively achieve glycemic targets, improve quality of life, add greater convenience, potentially reduce burden of care, and offer a personalized approach to self-management. Furthermore, diabetes technology canimprove the efficiency and effectiveness of clinical decision-making. Successful integration of thesetechnologies into care requires knowledge about the functionality of devices in this rapidly changingfield. This information will allow health care professionals to provide necessary education and training topersons accessing these treatments and have the required expertise to interpret data and makeappropriate treatment adjustments...

Obesity is an emerging condition, with a prevalence of ~20%. Al though the simple measurement of BMI is likely a simplistic approach to obesity, BMI is easily calculated, and there are currently no data showing that more sophisticated methods are more useful to guide the endocrine wo rk-up in obesity. An increased BMI leads to a number of hormonal changes. Additionally, concomitant hormonal diseases can be present in obesity and have to be properly diagnosed – which in turn might be more difficult d ue to alterations caused by body fatness itself. The present European Society of Endocrinology Clinical Guidelin e on the Endocrine Work-up in Obesity acknowledges the increased prevalence of many endocrine conditi ons in obesity. It is recommended to test all patients with obesity for thyroid function, given the high prevalence of hypothyroidism in obesity. For hypercortisolism, male hypogonadism and female gonadal dysfunct ion, hormonal testing is only recommended if case of clinical suspicion of an underlying endocrine disorder. The guideline underlines that weight loss in obesity should be emphasized as key to restoration of hormonal imbalanc es and that treatment and that the effect of treating endocrine disorders on weight loss is only modest.  ...